Purification and concentration of non-infectious West Nile virus-like particles and infectious virions using a pseudo-affinity Cellufine Sulfate column

Journal of Virological Methods

Volumn 174, Issue 1-2, 2011, Pages 131-135

  Ohtaki, Naohiro ^a   Takahashi, Hidehiro ^a   Kaneko, Keiko ^a   Gomi, Yasuyuki ^b   Ishikawa, Toyokazu ^b   Higashi, Yasushi ^b   Todokoro, Masami ^c   Kurata, Takeshi ^a   Sata, Tetsutaro ^a   Kojima, Asato ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b The Research Foundation for Microbial Diseases of Osaka University   (Japan)

^c CHISSO CORPORATION   (Japan)

Author keywords

Cellufine Sulfate; Column chromatography; Particulate antigen; West Nile virus

Indexed keywords

CELLUFINE SULFATE; DEXTRAN SULFATE; HEPARIN; POLYSACCHARIDE SULFATE; PROTEIN; SODIUM CHLORIDE; SULFATE; SURAMIN; UNCLASSIFIED DRUG; VIRUS ANTIGEN; WEST NILE VIRUS ANTIGEN;

AFFINITY COLUMN CHROMATOGRAPHY; ANTIGEN PURIFICATION; ARTICLE; COLUMN CHROMATOGRAPHY; CONTROLLED STUDY; E GENE; GENE EXPRESSION; IMMUNOGENICITY; NONHUMAN; PLAQUE FORMING CELL; PRIORITY JOURNAL; PRM GENE; SUPERNATANT; VIRION; VIRUS CHARACTERIZATION; VIRUS CONCENTRATION; VIRUS CULTURE; VIRUS GENE; VIRUS LIKE AGENT; VIRUS MORPHOLOGY; WEST NILE FLAVIVIRUS;

ANIMALS; CHROMATOGRAPHY, AFFINITY; CHROMATOGRAPHY, LIQUID; MICE; VIRION; VIROLOGY; VIROSOMES; WEST NILE VIRUS;

FLAVIVIRUS; MUS; WEST NILE VIRUS;

EID: 79955770870     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2011.03.021     Document Type: Article

References (22)

1. Baba M., Snoeck R., Pauwels R., de Clercq E. Sulfated polysaccharides are potent and selective inhibitors of various enveloped viruses, including herpes simplex virus, cytomegalovirus, vesicular stomatitis virus, and human immunodeficiency virus. Antimicrob. Agents Chemother. 1988, 32:1742-1745.
2. Bartz S.R., Pauza C.D., Ivanyi J., Jindal S., Welch W.J., Malkovsky M. An Hsp60 related protein is associated with purified HIV and SIV. J. Med. Primatol. 1994, 23:151-154.
3. Chen Y., Maguire T., Hileman R.E., Fromm J.R., Esko J.D., Linhardt R.J., Marks R.M. Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat. Med. 1997, 3:866-871.
4. Dauphin G., Zientara S. West Nile virus: recent trends in diagnosis and vaccine development. Vaccine 2007, 25:5563-5576.
5. Ehrlich H.J., Pavlova B.G., Fritsch S., Poellabauer E.M., Loew-Baselli A., Obermann-Slupetzky O., Maritsch F., Cil I., Dorner F., Barrett P.N. Randomized, phase II dose-finding studies of a modified tick-borne encephalitis vaccine: evaluation of safety and immunogenicity. Vaccine 2003, 22:217-223.
6. Hanna S.L., Pierson T.C., Sanchez M.D., Ahmed A.A., Murtadha M.M., Doms R.W. N-linked glycosylation of West Nile virus envelope proteins influences particle assembly and infectivity. J. Virol. 2005, 79:13262-13274.
7. Heinz F.X., Allison S.L., Stiasny K., Schalich J., Holzmann H., Mandl C.W., Kunz C. Recombinant and virion-derived soluble and particulate immunogens for vaccination against tick-borne encephalitis. Vaccine 1995, 13:1636-1642.
8. Lee E., Pavy M., Young N., Freeman C., Lobigs M. Antiviral effect of the heparan sulfate mimetic PI-88, against dengue and encephalitic flaviviruses. Antiviral Res. 2006, 69:31-38.
9. Lim C.K., Takasaki T., Kotaki A., Kurane I. Vero cell-derived inactivated West Nile (WN) vaccine induces protective immunity against lethal WN virus infection in mice and shows a facilitated neutralizing antibody response in mice previously immunized with Japanese encephalitis vaccine. Virology 2008, 374:60-70.
10. Monath T.P., Liu J., Kanesa-Thasan N., Myers G.A., Nichols R., Deary A., McCarthy K., Johnson C., Ermak T., Shin S., Arroyo J., Guirakhoo F., Kennedy J.S., Ennis F.A., Green S., Bedford P. A live, attenuated recombinant West Nile virus vaccine. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:6694-6699.
11. Ohtaki E., Matsuishi T., Hirano Y., Maekawa K. Acute disseminated encephalomyelitis after treatment with Japanese B encephalitis vaccine (Nakayama-Yoken and Beijing strains). J. Neurol. Neurosurg. Psychiatry 1995, 59:316-317.
12. Ohtaki N., Takahashi H., Kaneko K., Gomi Y., Ishikawa T., Higashi Y., Kurata T., Tetsutaro Sata T., Kojima A. Immunogenicity and efficacy of two types of West Nile virus-like particles different in size and maturation as a second-generation vaccine candidate. Vaccine 2010, 28:6588-6596.
13. O'Neil P.F., Balkovic E.S. Virus harvesting and affinity-based liquid chromatography A method for virus concentration and purification. Biotechnology (N. Y.) 1993, 11:173-178.
14. Opitz L., Lehmann S., Reichl U., Wolff M.W. Sulfated membrane adsorbers for economic pseudo-affinity capture of influenza virus particles. Biotechnol. Bioeng. 2009, 103:1144-1154.
15. Pletnev A.G., Swayne D.E., Speicher J., Rumyantsev A.A., Murphy B.R. Chimeric West Nile/dengue virus vaccine candidate: preclinical evaluation in mice, geese and monkeys for safety and immunogenicity. Vaccine 2006, 24:6392-6404.
16. Schalich J., Allison S.L., Stiasny K., Mandl C.W., Kunz C., Heinz F.X. Recombinant subviral particles from tick-borne encephalitis virus are fusogenic and provide a model system for studying flavivirus envelope glycoprotein functions. J. Virol. 1996, 70:4549-4557.
17. Su C.M., Liao C.L., Lee Y.L., Lin Y.L. Highly sulfated forms of heparin sulfate are involved in Japanese encephalitis virus infection. Virology 2001, 286:206-215.
18. Sugawara K., Nishiyama K., Ishikawa Y., Abe M., Sonoda K., Komatsu K., Horikawa Y., Takeda K., Honda T., Kuzuhara S., Kino Y., Mizokami H., Mizuno K., Oka T., Honda K. Development of Vero cell-derived inactivated Japanese encephalitis vaccine. Biologicals 2002, 30:303-314.
19. Takahashi H., Ohtaki N., Maeda-Sato M., Tanaka M., Tanaka K., Sawa H., Ishikawa T., Takamizawa A., Takasaki T., Hasegawa H., Sata T., Hall W.W., Kurata T., Kojima A. Effects of the number of amino acid residues in the signal segment upstream or downstream of the NS2B-3 cleavage site on production and secretion of prM/M-E virus-like particles of West Nile virus. Microbes Infect. 2009, 11:1019-1028.
20. Toriniwa H., Komiya T. Long-term stability of Vero cell-derived inactivated Japanese encephalitis vaccine prepared using serum-free medium. Vaccine 2008, 26:3680-3689.
21. Widman D.G., Ishikawa T., Fayzulin R., Bourne N., Mason P.W. Construction and characterization of a second-generation pseudoinfectious West Nile virus vaccine propagated using a new cultivation system. Vaccine 2008, 26:2762-2771.
22. Witvrouw M., De Clercq E. Sulfated polysaccharides extracted from sea algae as potential antiviral drugs. Gen. Pharmacol. 1997, 29:497-511.